- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06357533
Fase III, open-label onderzoek naar eerstelijns Dato-DXd in combinatie met Rilvegostomig voor gevorderd niet-plaveiselcel-NSCLC met hoge PD-L1-expressie (TC ≥ 50%) en zonder bruikbare genomische veranderingen (TROPION-Lung10)
Een fase III, gerandomiseerde, open-label, mondiale studie van Datopotamab Deruxtecan (Dato-DXd) in combinatie met Rilvegostomig of Rilvegostomig monotherapie versus pembrolizumab monotherapie voor de eerstelijnsbehandeling van deelnemers met lokaal gevorderd of gemetastaseerd niet-plaveiselcel-NSCLC met hoge PD-L1-expressie (TC ≥ 50%) en zonder bruikbare genomische veranderingen (TROPION-Lung10)
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy compared with Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: AstraZeneca Clinical Study Information Center
- Telefoonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studie Locaties
-
-
-
Birtinya, Australië, 4575
- Ingetrokken
- Research Site
-
Blacktown, Australië, 2148
- Ingetrokken
- Research Site
-
Clayton, Australië, 3168
- Werving
- Research Site
-
Gosford, Australië, 2250
- Werving
- Research Site
-
Melbourne, Australië, 3000
- Ingetrokken
- Research Site
-
South Brisbane, Australië, QL 4101
- Werving
- Research Site
-
Wodonga, Australië, 3690
- Werving
- Research Site
-
-
-
-
-
Anderlecht, België, 1070
- Ingetrokken
- Research Site
-
Bruges, België, 8000
- Werving
- Research Site
-
Hasselt, België, 3500
- Werving
- Research Site
-
La Louvière, België, 7100
- Werving
- Research Site
-
Liège, België, 4000
- Werving
- Research Site
-
-
-
-
-
Barretos, Brazilië, 14784-400
- Werving
- Research Site
-
Curitiba, Brazilië, 80730-150
- Werving
- Research Site
-
Florianópolis, Brazilië, 88034-000
- Werving
- Research Site
-
Ipatinga, Brazilië, 35162-189
- Werving
- Research Site
-
Natal, Brazilië, 59075-740
- Werving
- Research Site
-
Porto Alegre, Brazilië, 91350-200
- Werving
- Research Site
-
Rio de Janeiro, Brazilië, 22211-230
- Werving
- Research Site
-
Santa Maria, Brazilië, 97015-450
- Werving
- Research Site
-
São Paulo, Brazilië, 01221-020
- Werving
- Research Site
-
Taubaté, Brazilië, 12030-200
- Werving
- Research Site
-
-
-
-
-
Chicoutimi, Canada, G7H 5H6
- Werving
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, VSZ 4E6
- Werving
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Ingetrokken
- Research Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Werving
- Research Site
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- Werving
- Research Site
-
Newmarket, Ontario, Canada, L3Y 2P9
- Ingetrokken
- Research Site
-
Oshawa, Ontario, Canada, L1G 2B9
- Werving
- Research Site
-
Toronto, Ontario, Canada, M4N 3M5
- Ingetrokken
- Research Site
-
-
Quebec
-
Lévis, Quebec, Canada, G6V 0B8
- Werving
- Research Site
-
Montreal, Quebec, Canada, H4J 1C5
- Werving
- Research Site
-
Montreal, Quebec, Canada, H3T 1E2
- Werving
- Research Site
-
Montreal, Quebec, Canada, H3T 1M5
- Ingetrokken
- Research Site
-
Rimouski, Quebec, Canada, G5L 5T1
- Werving
- Research Site
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Werving
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Werving
- Research Site
-
-
-
-
-
Beijing, China, 100142
- Werving
- Research Site
-
Beijing, China, 101149
- Werving
- Research Site
-
Changchun, China, 130000
- Werving
- Research Site
-
Changsha, China, 410013
- Werving
- Research Site
-
Chengdu, China, 610000
- Werving
- Research Site
-
Chengdu, China, 610041
- Werving
- Research Site
-
Chongqing, China, 400030
- Werving
- Research Site
-
Fuzhou, China, 350014
- Werving
- Research Site
-
Guangzhou, China, 510080
- Werving
- Research Site
-
Hangzhou, China, 310006
- Werving
- Research Site
-
Hangzhou, China, 310022
- Werving
- Research Site
-
Hangzhou, China, 310016
- Werving
- Research Site
-
Harbin, China, 150049
- Werving
- Research Site
-
Hefei, China, 230601
- Werving
- Research Site
-
Hefei, China, 230031
- Ingetrokken
- Research Site
-
Jinan, China, 250117
- Werving
- Research Site
-
Jining, China, 272011
- Ingetrokken
- Research Site
-
Kunming, China, 650118
- Werving
- Research Site
-
Lanzhou, China, 730000
- Werving
- Research Site
-
Linhai, China, 317000
- Werving
- Research Site
-
Linyi, China, 276001
- Werving
- Research Site
-
Nanjing, China, 210009
- Werving
- Research Site
-
Nanning, China, 530021
- Werving
- Research Site
-
Nanning, China, 530000
- Werving
- Research Site
-
Shanghai, China, 200032
- Werving
- Research Site
-
Shanghai, China, 200030
- Werving
- Research Site
-
Shanghai, China, 200433
- Werving
- Research Site
-
Shenyang, China, 110022
- Werving
- Research Site
-
Taiyuan, China, 030000
- Werving
- Research Site
-
Tianjin, China, 300060
- Werving
- Research Site
-
Wenzhou, China, 325000
- Werving
- Research Site
-
Wuhan, China, 430022
- Werving
- Research Site
-
Wuhan, China, 430030
- Werving
- Research Site
-
Wuhan, China, 430010
- Werving
- Research Site
-
Wuhan, China, 430000
- Werving
- Research Site
-
Xi'an, China, 710061
- Werving
- Research Site
-
Yangzhou, China, 225001
- Werving
- Research Site
-
Zhengzhou, China, 450000
- Werving
- Research Site
-
Zhengzhou, China, 450008
- Werving
- Research Site
-
-
-
-
-
Berlin, Duitsland, 10249
- Nog niet aan het werven
- Research Site
-
Bonn, Duitsland, 53113
- Werving
- Research Site
-
Cologne, Duitsland, 50677
- Werving
- Research Site
-
Düsseldorf, Duitsland, 40489
- Ingetrokken
- Research Site
-
Essen, Duitsland, 45136
- Werving
- Research Site
-
Freiburg im Breisgau, Duitsland, 79106
- Werving
- Research Site
-
Gauting, Duitsland, 82131
- Werving
- Research Site
-
Georgsmarienhütte, Duitsland, 49124
- Ingetrokken
- Research Site
-
Gera, Duitsland, 07548
- Ingetrokken
- Research Site
-
Gütersloh, Duitsland, 33332
- Ingetrokken
- Research Site
-
Hamburg, Duitsland, 20251
- Werving
- Research Site
-
Hamburg, Duitsland, 22087
- Werving
- Research Site
-
Heidelberg, Duitsland, 69126
- Werving
- Research Site
-
Kempten, Duitsland, 87439
- Geschorst
- Research Site
-
Kiel, Duitsland, 24116
- Nog niet aan het werven
- Research Site
-
Koblenz, Duitsland, 56068
- Geschorst
- Research Site
-
Ludwigsburg, Duitsland, 71640
- Ingetrokken
- Research Site
-
München, Duitsland, 81925
- Werving
- Research Site
-
Nuremberg, Duitsland, 90419
- Ingetrokken
- Research Site
-
Potsdam, Duitsland, 14467
- Werving
- Research Site
-
Ravensburg, Duitsland, 88212
- Werving
- Research Site
-
-
-
-
-
Budapest, Hongarije, 1121
- Werving
- Research Site
-
Edelény, Hongarije, 3780
- Nog niet aan het werven
- Research Site
-
Gyula, Hongarije, 5700
- Geschorst
- Research Site
-
Gyöngyös, Hongarije, 3200
- Ingetrokken
- Research Site
-
Gyöngyös - Mátraháza, Hongarije, 3200
- Werving
- Research Site
-
Győr, Hongarije, 9024
- Werving
- Research Site
-
Kecskemét, Hongarije, 6000
- Werving
- Research Site
-
Salgótarján, Hongarije, 3100
- Ingetrokken
- Research Site
-
Szekszárd, Hongarije, 7100
- Werving
- Research Site
-
Szolnok, Hongarije, 5000
- Ingetrokken
- Research Site
-
Székesfehérvár, Hongarije, 8000
- Ingetrokken
- Research Site
-
Törökbálint, Hongarije, 2045
- Werving
- Research Site
-
-
-
-
-
Chennai, Indië, 600031
- Werving
- Research Site
-
Dwārka, Indië, 110075
- Werving
- Research Site
-
Jaipur, Indië, 302004
- Werving
- Research Site
-
Kolkata, Indië, 700099
- Werving
- Research Site
-
Marg Jaipur, Indië, 302004
- Ingetrokken
- Research Site
-
Nagpur, Indië, 440001
- Werving
- Research Site
-
Nashik, Indië, 422011
- Werving
- Research Site
-
New Delhi, Indië, 11029
- Werving
- Research Site
-
New Delhi, Indië, 110085
- Werving
- Research Site
-
Surat, Indië, 395002
- Werving
- Research Site
-
Thiruvananthapuram, Indië, 695011
- Ingetrokken
- Research Site
-
-
-
-
-
Bergamo, Italië, 24125
- Werving
- Research Site
-
Genoa, Italië, 16132
- Werving
- Research Site
-
Milan, Italië, 20141
- Werving
- Research Site
-
Milan, Italië, 20162
- Werving
- Research Site
-
Monza, Italië, 20052
- Werving
- Research Site
-
Padova, Italië, 35128
- Werving
- Research Site
-
Pavia, Italië, 27100
- Werving
- Research Site
-
Ravenna, Italië, 48100
- Werving
- Research Site
-
Roma, Italië, 00128
- Werving
- Research Site
-
Rozzano, Italië, 20089
- Werving
- Research Site
-
-
-
-
-
Bunkyō City, Japan, 113-8431
- Werving
- Research Site
-
Bunkyō City, Japan, 160-0023
- Werving
- Research Site
-
Fukuoka, Japan, 812-8582
- Werving
- Research Site
-
Fukuoka, Japan, 814-0180
- Werving
- Research Site
-
Hakodate-shi, Japan, 040-8611
- Werving
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Werving
- Research Site
-
Hirakata-shi, Japan, 573-1191
- Werving
- Research Site
-
Hirosaki-shi, Japan, 036-8563
- Werving
- Research Site
-
Hiroshima, Japan, 730-8518
- Werving
- Research Site
-
Kanazawa, Japan, 920-8641
- Werving
- Research Site
-
Kashiwa, Japan, 227-8577
- Werving
- Research Site
-
Kawasaki-shi, Japan, 216-8511
- Werving
- Research Site
-
Kumamoto, Japan, 860-8556
- Werving
- Research Site
-
Matsusaka-shi, Japan, 515-8544
- Werving
- Research Site
-
Matsuyama, Japan, 790-0024
- Werving
- Research Site
-
Nagoya, Japan, 460-0001
- Werving
- Research Site
-
Niigata, Japan, 951-8566
- Werving
- Research Site
-
Okayama, Japan, 700-8558
- Werving
- Research Site
-
Osaka, Japan, 545-8586
- Ingetrokken
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Werving
- Research Site
-
Sagamihara-shi, Japan, 252-0375
- Werving
- Research Site
-
Sapporo, Japan, 003-0804
- Werving
- Research Site
-
Takaoka-shi, Japan, 933-8555
- Werving
- Research Site
-
Takatsuki-shi, Japan, 569-8686
- Werving
- Research Site
-
Tokushima, Japan, 770-8503
- Werving
- Research Site
-
Tokyo, Japan, 104-0045
- Werving
- Research Site
-
Utsunomiya, Japan, 320-0834
- Werving
- Research Site
-
Yokohama, Japan, 221-0855
- Werving
- Research Site
-
-
-
-
-
Innsbruck, Oostenrijk, 6020
- Werving
- Research Site
-
Krems, Oostenrijk, 3500
- Werving
- Research Site
-
Linz, Oostenrijk, 4020
- Werving
- Research Site
-
Rankweil, Oostenrijk, 6830
- Werving
- Research Site
-
Vienna, Oostenrijk, 1210
- Werving
- Research Site
-
Vienna, Oostenrijk, 1140
- Werving
- Research Site
-
Wels, Oostenrijk, 4600
- Ingetrokken
- Research Site
-
-
-
-
-
Olsztyn, Polen, 10-357
- Werving
- Research Site
-
Poznan, Polen, 60-569
- Werving
- Research Site
-
Przemyśl, Polen, 37-700
- Werving
- Research Site
-
Warsaw, Polen, 02-781
- Werving
- Research Site
-
Warsaw, Polen, 01-138
- Werving
- Research Site
-
-
-
-
-
San Juan, Puerto Rico, 00909
- Werving
- Research Site
-
-
-
-
-
Alicante, Spanje, 03010
- Werving
- Research Site
-
Barcelona, Spanje, 08036
- Werving
- Research Site
-
Barcelona, Spanje, 08003
- Werving
- Research Site
-
Barcelona, Spanje, 08041
- Nog niet aan het werven
- Research Site
-
Jerez de la Frontera, Spanje, 11407
- Werving
- Research Site
-
Reus, Spanje, 43204
- Werving
- Research Site
-
Salamanca, Spanje, 37007
- Ingetrokken
- Research Site
-
-
-
-
-
Changhua, Taiwan, 500
- Nog niet aan het werven
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Werving
- Research Site
-
New Taipei City, Taiwan, 220
- Werving
- Research Site
-
Taichung, Taiwan, 40447
- Werving
- Research Site
-
Taichung, Taiwan, 40705
- Werving
- Research Site
-
Tainan, Taiwan, 704
- Werving
- Research Site
-
Taipei, Taiwan, TAIWAN
- Werving
- Research Site
-
Taipei, Taiwan, 10002
- Werving
- Research Site
-
Taipei, Taiwan, 112
- Werving
- Research Site
-
Taipei, Taiwan, 0116
- Werving
- Research Site
-
Taoyuan, Taiwan, 333
- Werving
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Werving
- Research Site
-
Bangkok, Thailand, 10700
- Werving
- Research Site
-
Hat Yai, Thailand, 90110
- Werving
- Research Site
-
Muang, Thailand, 22000
- Werving
- Research Site
-
Mueang, Thailand, 20000
- Werving
- Research Site
-
Mueang, Thailand, 32000
- Werving
- Research Site
-
-
-
-
-
Adapazarı, Turkije (Türkiye), 54100
- Werving
- Research Site
-
Ankara, Turkije (Türkiye), 6200
- Werving
- Research Site
-
Ankara, Turkije (Türkiye), 06560
- Werving
- Research Site
-
Antalya, Turkije (Türkiye), 07070
- Werving
- Research Site
-
Diyarbakır, Turkije (Türkiye), 21280
- Werving
- Research Site
-
Istanbul, Turkije (Türkiye), 34030
- Werving
- Research Site
-
Istanbul, Turkije (Türkiye), 34890
- Werving
- Research Site
-
-
-
-
-
Cheltenham, Verenigd Koninkrijk, GL53 7AN
- Geschorst
- Research Site
-
Inverness, Verenigd Koninkrijk, IV2 3UJ
- Geschorst
- Research Site
-
London, Verenigd Koninkrijk, SW17 0QT
- Werving
- Research Site
-
London, Verenigd Koninkrijk, SW10 9NH
- Werving
- Research Site
-
London, Verenigd Koninkrijk, SE1 9RT
- Ingetrokken
- Research Site
-
Norwich, Verenigd Koninkrijk, NR4 7UY
- Werving
- Research Site
-
Preston, Verenigd Koninkrijk, PR2 9HT
- Werving
- Research Site
-
Truro, Verenigd Koninkrijk, TR1 3LJ
- Werving
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, Verenigde Staten, 99508
- Werving
- Research Site
-
-
Arizona
-
Tucson, Arizona, Verenigde Staten, 85719
- Werving
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- Werving
- Research Site
-
Springdale, Arkansas, Verenigde Staten, 72762
- Werving
- Research Site
-
-
California
-
Anaheim, California, Verenigde Staten, 92801
- Werving
- Research Site
-
Beverly Hills, California, Verenigde Staten, 90211
- Werving
- Research Site
-
Fountain Valley, California, Verenigde Staten, 92708
- Werving
- Research Site
-
Newport Beach, California, Verenigde Staten, 92663
- Geschorst
- Research Site
-
-
Florida
-
Clermont, Florida, Verenigde Staten, 34711
- Werving
- Research Site
-
Gainesville, Florida, Verenigde Staten, 32608
- Werving
- Research Site
-
Miami Beach, Florida, Verenigde Staten, 33140
- Werving
- Research Site
-
Orange City, Florida, Verenigde Staten, 32763
- Werving
- Research Site
-
Orlando, Florida, Verenigde Staten, 32806
- Werving
- Research Site
-
Orlando, Florida, Verenigde Staten, 32827
- Ingetrokken
- Research Site
-
West Palm Beach, Florida, Verenigde Staten, 33401
- Werving
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Research Site
-
Atlanta, Georgia, Verenigde Staten, 30318
- Werving
- Research Site
-
Atlanta, Georgia, Verenigde Staten, 30342
- Ingetrokken
- Research Site
-
Atlanta, Georgia, Verenigde Staten, 30303
- Geschorst
- Research Site
-
-
Illinois
-
Hinsdale, Illinois, Verenigde Staten, 60521
- Werving
- Research Site
-
-
Indiana
-
Noblesville, Indiana, Verenigde Staten, 46062
- Werving
- Research Site
-
-
Kentucky
-
Paducah, Kentucky, Verenigde Staten, 42003
- Werving
- Research Site
-
-
Maryland
-
Annapolis, Maryland, Verenigde Staten, 21401
- Werving
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Research Site
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Research Site
-
-
Michigan
-
Dearborn, Michigan, Verenigde Staten, 48126
- Werving
- Research Site
-
Farmington Hills, Michigan, Verenigde Staten, 48334
- Werving
- Research Site
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Werving
- Research Site
-
Traverse City, Michigan, Verenigde Staten, 49684
- Ingetrokken
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, Verenigde Staten, 39401
- Werving
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64132
- Werving
- Research Site
-
-
Montana
-
Bozeman, Montana, Verenigde Staten, 59715
- Ingetrokken
- Research Site
-
-
Nebraska
-
Grand Island, Nebraska, Verenigde Staten, 68803
- Werving
- Research Site
-
Omaha, Nebraska, Verenigde Staten, 68130
- Werving
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89102
- Werving
- Research Site
-
Reno, Nevada, Verenigde Staten, 89502
- Ingetrokken
- Research Site
-
-
New Jersey
-
Voorhees Township, New Jersey, Verenigde Staten, 08043
- Geschorst
- Research Site
-
-
New York
-
Stony Brook, New York, Verenigde Staten, 11794
- Werving
- Research Site
-
-
North Carolina
-
Greenville, North Carolina, Verenigde Staten, 27834
- Werving
- Research Site
-
Salisbury, North Carolina, Verenigde Staten, 28144
- Werving
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Werving
- Research Site
-
Columbus, Ohio, Verenigde Staten, 43210
- Ingetrokken
- Research Site
-
Maumee, Ohio, Verenigde Staten, 43537
- Werving
- Research Site
-
Toledo, Ohio, Verenigde Staten, 43623
- Werving
- Research Site
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97213
- Ingetrokken
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29607
- Werving
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57105
- Werving
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten, 37404
- Ingetrokken
- Research Site
-
Knoxville, Tennessee, Verenigde Staten, 37920
- Ingetrokken
- Research Site
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- Research Site
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Research Site
-
Houston, Texas, Verenigde Staten, 77030
- Ingetrokken
- Research Site
-
Houston, Texas, Verenigde Staten, 77090
- Geschorst
- Research Site
-
Kingwood, Texas, Verenigde Staten, 77339
- Werving
- Research Site
-
Odessa, Texas, Verenigde Staten, 79761
- Werving
- Research Site
-
-
Virginia
-
Fort Belvoir, Virginia, Verenigde Staten, 22060
- Werving
- Research Site
-
Leesburg, Virginia, Verenigde Staten, 20176
- Werving
- Research Site
-
Midlothian, Virginia, Verenigde Staten, 23114
- Werving
- Research Site
-
Richmond, Virginia, Verenigde Staten, 23230
- Werving
- Research Site
-
-
Washington
-
Tacoma, Washington, Verenigde Staten, 98405
- Werving
- Research Site
-
Vancouver, Washington, Verenigde Staten, 98684
- Werving
- Research Site
-
Wenatchee, Washington, Verenigde Staten, 98801
- Werving
- Research Site
-
-
Wisconsin
-
Appleton, Wisconsin, Verenigde Staten, 54911
- Werving
- Research Site
-
-
-
-
-
Da Nang, Vietnam, 550000
- Werving
- Research Site
-
Hanoi, Vietnam, 100000
- Werving
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Werving
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Ingetrokken
- Research Site
-
Huế, Vietnam, 530000
- Ingetrokken
- Research Site
-
Hà Nội, Vietnam, 100000
- Werving
- Research Site
-
Vinh, Vietnam, 460000
- Ingetrokken
- Research Site
-
Vĩnh Yên, Vietnam, 280000
- Werving
- Research Site
-
-
-
-
-
Changwon, Zuid -Korea, 51353
- Werving
- Research Site
-
Incheon, Zuid -Korea, 21565
- Werving
- Research Site
-
Seongnam-si, Zuid -Korea, 13496
- Werving
- Research Site
-
Seoul, Zuid -Korea, 03080
- Werving
- Research Site
-
Seoul, Zuid -Korea, 03722
- Werving
- Research Site
-
Seoul, Zuid -Korea, 08308
- Nog niet aan het werven
- Research Site
-
Seoul, Zuid -Korea, 06973
- Werving
- Research Site
-
Suwon, Zuid -Korea, 16247
- Werving
- Research Site
-
Suwon, Zuid -Korea, 16499
- Werving
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologically or cytologically documented non-squamous NSCLC.
- Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
- Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
- Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
- Known tumour PD-L1 expression status defined as TC ≥ 50%
- At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
- ECOG performance status of 0 or 1
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Prior systemic therapy for advanced/metastatic NSCLC.
- Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
- History of another primary malignancy within 3 years
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
- Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
- History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Has significant pulmonary function compromise, as determined by the investigator
- Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
- History of leptomeningeal carcinomatosis
- Known clinically significant corneal disease
- Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig
Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Datopotamab Deruxtecan IV (intravenous)
Andere namen:
Rilvegostomig IV (intravenous)
Andere namen:
|
|
Experimenteel: Arm 2: Rilvegostomig Monotherapy
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Rilvegostomig IV (intravenous)
Andere namen:
|
|
Actieve vergelijker: Arm 3: Pembrolizumab Monotherapy
Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Pembrolizumab IV (intravenous)
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
Tijdsspanne: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in TROP2 biomarker positive participants.
Tijdsspanne: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of OS. |
Approximately 6 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS) in the FAS population.
Tijdsspanne: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • FAS population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in the FAS population.
Tijdsspanne: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • FAS population The measure of interest is the HR of OS. |
Approximately 6 years
|
|
Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations
Tijdsspanne: Approximately 4 years
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1. The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:
The measure of interest is the difference of the ORR. ORR by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations
Tijdsspanne: Approximately 4 years
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR or death due to any cause. The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:
|
Approximately 4 years
|
|
Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.
Tijdsspanne: Approximately 6 years
|
Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.
Tijdsspanne: Approximately 6 years
|
Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Pharmacokinetics (PK)
Tijdsspanne: Approximately 6 years
|
Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations). |
Approximately 6 years
|
|
Immunogenicity
Tijdsspanne: Approximately 6 years
|
Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples). |
Approximately 6 years
|
|
Second Progression-Free Survival (PFS2).
Tijdsspanne: Approximately 6 years
|
PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice. The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:
|
Approximately 6 years
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab.
Tijdsspanne: Approximately 6 years
|
Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0). |
Approximately 6 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Suresh S. Ramalingam, MD, Emory University, Atlanta, Georgia, United States of America.
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- D7632C00001
- 2023-505077-32-00 (Register-ID: CTIS (EU))
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD-tijdsbestek voor delen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD-toegangscriteria voor delen
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .